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Editorial
It has been at least three decades since radiobiological mod-
els based on dose volume histograms (DVH) or
3-dimensional dose distributions started appearing in the
literature as means to evaluate and compare radiotherapy
treatment plans. Since then, many studies have shown that
radiobiological treatment plan evaluation provides a closer
association of the delivered treatment with the clinical out-
come. This is achieved by taking into account the
dose-response characteristics of the irradiated targets and
normal tissues involved. In radiobiological treatment plan-
ning, biological tissue information and physical data have a
complementary relation in analyzing dose plans due to the
fact that both are incorporated in the mathematical expres-
sions of the radiobiological models.
However, although the necessity of using radiobiological
models in radiotherapy has been proven, their clinical im-
plementation until now is almost negligible. Even the bio-
logical effective dose (BED) that was introduced in the early
80s has mainly been used to associate the maximum BED
values of certain tissues with the respective risk for compli-
cations. And even though it has become a common
knowledge that BED is a more accurate descriptor of the
biological effectiveness of the applied physical dose, its clin-
ical use is still limited. It is only during the recent years that
BED started being used for dose prescription purposes in-
stead of the physical dose or for determining BED-related
dose thresholds for normal tissues. Furthermore, although
the different treatment planning systems (TPS) have recently
implemented the calculation of BED values, they still do not
provide BED volume histograms or 3-dimenstional BED
distributions or iso-BED line charts or the possibility of cal-
culating the composite BED values in treatments composed
by multiple phases. Usually, the clinical implementation of a
new concept in radiotherapy is the result of the synergetic
action between the clinical need and the availability of the
relevant tools by the different TPSs.
The facts described above for the BED concept to a large
extent hold for the clinical implementation of radiobiologi-
cal models, namely the models that estimate the tumor con-
trol probability (TCP), normal tissue complication probabil-
ity (NTCP) and complication-free tumor control probability
(P+). These models use radiobiological parameters that de-
scribe the dose-response relations of the different tumors
and normal tissues. The derivation of the model parameters
can be performed by different means such as a maximum
likelihood fitting using a cohort of patients for whom the
delivered 3-dimensional dose distributions and fractionation
scheme as well as the relevant treatment related organ re-
sponses have been registered. Although radiobiological mod-
els use the complete dosimetric information of a given
treatment plan in order to quantify its quality, in clinical
practice dose prescription and treatment plan evaluation are
based on single doses in the tumor, mean physical doses to
the PTV or physical dose-volume points to the tumor and
involved organs at risk (OARs), which however take into
account a fraction only of the treatment information. Fur-
thermore, the values of those treatment plan quality de-
scriptors are usually characterized by large uncertainty in-
tervals, which however are not taken into account clinically.
The current status of treatment planning practice is the re-
sult of the traditional approach of using dosimetric de-
scriptors for quantifying the quality of treatment plans and
the fact that the values of these descriptors could be calcu-
lated by the TPS, which made their clinical implementation
easier. However, all these descriptors are indirectly related
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with treatment plan quality and they do not answer to the fundamental questions of ‘what if the likelihood to achieve tumor
control’ or ‘what is the likelihood to have side effects to the OARs’ when evaluating a given treatment plan. These answers are
provided by the TCP and NTCP measures irrespective of the treatment technique, cancer site, fractionation scheme or clinical
protocol applied. So, although radiobiological models convey to a larger extent the clinical insight and the values of their pa-
rameters are more accurate compared to those of the descriptors that are used clinically, their clinical implementation is negli-
gible.
There are two main reasons for this. First, there is lack of understanding the theory and the basic concepts behind radiobiologi-
cal modeling by many radiation oncologists. It can be easily shown that the classes devoted to radiobiological modeling either
during the university studies or during the medical residency programs are very limited in number and extent. Second and
more important, is the fact that only recently some TPS started offering some tools for performing radiobiological evaluation
and comparison of different treatment plans. But still this is not adequate because in order these tools to be used clinically, one
has to reach the point of having established radiobiological treatment planning as a clinically implemented procedure.
In order to reach this point, the different TPS should offer to the clinician’s tools that will help them organize their patient
treatment information and follow-up registrations in order to enable them determine the values of the radiobiological parame-
ters of the models they want to use, based on their own patient data. Appropriate tools should be offered for performing clinical
verification of such clinically derived parameter values as well as for performing clinical validation of parameter sets found in
the literature. By using those tools, patient datasets consisting of individual tissue response and dose distribution data can be
fitted by different radiobiological models and their goodness-of-fit can be evaluated. These are the important elements that are
missing for a clinical implementation of radiobiological modeling, the absence of which has led to this long delay in seeing a
reasonable progress in this issue.
Radiobiological treatment plan evaluation may allow a fairly accurate prediction of tumor control or normal tissue complica-
tions taking into account the variations in patient radiosensitivity. The use of radiobiological modeling is necessary if a clinical-
ly relevant quantification of a dose plan is needed.
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